Tag: FDA approvals for neuroendocrine cancer treatments

FDA approval 3

PRRT – FDA Approves Lutathera®, What’s Next?

February 20, 2018

The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community.  It has also raised a host of questions including:

  • What exactly is this
… READ MORE